Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.74 |
| ▸ | DRD3 | P35462 | 2/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.61 |
| ▸ | HRH1 | P35367 | 2/20 | 0.61 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.61 |
| ▸ | HTR1A | P08908 | 1/20 | 0.61 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.61 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.61 |
| ▸ | DRD2 | P14416 | 1/20 | 0.61 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.61 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.61 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.61 |
| ▸ | DRD4 | P21917 | 1/20 | 0.61 |
| ▸ | HRH2 | P25021 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.61 |
| ▸ | HTR2C | P28335 | 1/20 | 0.61 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.61 |
| ▸ | HTR2B | P41595 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29907915 | 1.00 | CYP2D6 (0.74) | CYP2D6DRD3SLC6A2HRH1CHRM2 | |
| SCHEMBL6219453 | 0.92 | CYP2D6 (0.65) | CYP2D6DRD3SLC6A2HRH1CHRM2 | |
| SCHEMBL10702688 | 0.90 | SLC6A4 (0.64) | CYP2D6DRD3SLC6A2HRH1CHRM2 | |
| SCHEMBL11826363 | 0.88 | CYP2D6 (0.59) | CYP2D6DRD3SLC6A2HRH1CHRM2 | |
| Fantridone SCHEMBL1683047 | 0.87 | PGR (0.69) | CYP2D6DRD3SLC6A2HRH1CHRM2 | |
| SCHEMBL11754129 | 0.86 | KDM4E (0.61) | CYP2D6DRD3SLC6A2HRH1CHRM2 | |
| SCHEMBL11834370 | 0.86 | CYP2D6 (0.59) | CYP2D6DRD3SLC6A2HRH1CHRM2 | |
| SCHEMBL17444583 | 0.86 | CYP2D6 (0.59) | CYP2D6DRD3SLC6A2HRH1CHRM2 | |
| Fantridone SCHEMBL124109 | 0.85 | PGR (0.68) | CYP2D6DRD3SLC6A2HRH1CHRM2 | |
| SCHEMBL15848971 | 0.84 | CYP2D6 (0.60) | CYP2D6DRD3SLC6A2HRH1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190082845-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | INCURON INC (US) | 2019-03-21 | — | — | US | disclosed |
| US-20190082845-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | INCURON INC (US) | 2019-03-21 | — | — | US | disclosed |
| US-10137109-B2 | Carbazole compounds and therapeutic uses of the compounds | INCURON, INC. (US) | 2018-11-27 | — | — | US | disclosed |
| US-20170165229-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | INCURON, INC. | 2017-06-15 | — | — | US | disclosed |
| US-20170165229-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | INCURON, INC. | 2017-06-15 | — | — | US | disclosed |
| US-20170165229-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | INCURON, INC. | 2017-06-15 | — | — | US | disclosed |
| US-9566265-B2 | Carbazole compounds and therapeutic uses of the compounds | INCURON, LLC (US) | 2017-02-14 | — | — | US | disclosed |
| US-9566265-B2 | Carbazole compounds and therapeutic uses of the compounds | INCURON, LLC (US) | 2017-02-14 | — | — | US | disclosed |
| US-9566265-B2 | Carbazole compounds and therapeutic uses of the compounds | INCURON, LLC (US) | 2017-02-14 | — | — | US | disclosed |
| CN-104341335-B | Amido carbazole bridging molecule tweezer and its preparation method and application | WUHAN INSTITUTE OF TECHNOLOGY (CN) | 2016-04-13 | — | — | CN | disclosed |
| US-20110305661-A1 | Carbazole Compounds and Therapeutic Uses of the Compounds | INCURON, INC. | 2011-12-15 | — | — | US | disclosed |
| EP-2356093-A1 | Carbazole compounds and therapeutic uses of the compounds | INCURON, LLC (RU) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010042445-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | CLEVELAND BIOLABS, INC. (US) | 2010-04-15 | — | — | WO | disclosed |
| WO-2010042445-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | CLEVELAND BIOLABS, INC. (US) | 2010-04-15 | — | — | WO | disclosed |
| US-7176322-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2007-02-13 | — | — | US | disclosed |
| EP-1509518-A1 | CALCIUM RECEPTOR MODULATING AGENTS | Amgen, Inc. (US) | 2005-03-02 | — | — | EP | disclosed |
| US-20040077619-A1 | Calcium receptor modulating agents | AMGEN INC. | 2004-04-22 | — | — | US | disclosed |
| WO-2003099814-A1 | CALCIUM RECEPTOR MODULATING AGENTS | AMGEN, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
| US-3988208-A | FOR GLUCOSE | BOEHRINGER MANNHEIM G.M.B.H. (DT) | 1976-10-26 | — | — | US | disclosed |
| US-3975398-A | INDICATOR FOR DETERMINATION OF GLUCOSE | BOEHRINGER MANNHEIM G.M.B.H. (DT) | 1976-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170165229-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | MALT1, PAICS, BCL9 | CYP2D6 233/4885DRD3 3411/4885SLC6A2 3683/4885 |
| US-20040077619-A1 | Calcium receptor modulating agents | PTH1R, CASR, CALCR | CYP2D6 4576/4885DRD3 2339/4885SLC6A2 1728/4885 |
| US-10137109-B2 | Carbazole compounds and therapeutic uses of the compounds | MALT1, PAICS, BCL9 | CYP2D6 233/4885DRD3 3411/4885SLC6A2 3683/4885 |
| US-20110305661-A1 | Carbazole Compounds and Therapeutic Uses of the Compounds | MALT1, PAICS, TPMT | CYP2D6 207/4885DRD3 3374/4885SLC6A2 3659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.